Dr. Yangchao Chen

Chinese University of Hong Kong, China

Associate Professor

Email: frankch@cuhk.edu.hk

Qualifications

2005 Postdoctoral Fellow, University of Washington, USA

2003 Ph.D., Sun Yat-Sen University, China

2000 M.Phil., Guangdong Medical College, China

Publications (Selected)

1. Feng R, Shou JW, Zhao ZX, He CY, Ma C, Huang M, Fu J, Tan XS, Li XY, Wen BY, Chen X, Yang XY, Ren G, Chen Y, You XF, Wang Y, Jiang JD. Transforming berberine into its intestine absorbable form by gut microbiota. Sci Rep. Accepted for publication.
2. Li CH, Chen Y. Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy.Current Genomics, 2015, 16(5): 319-326.
3. Zhu R, Mok MT, Kang W, Lau SS, Yip WK, Chen Y, Lai PB, Wong VW, To KF, Sung JJ, Cheng AS, Chan HL. Truncated HBx-dependent silencing of GAS2 promotes hepatocarcinogenesis through deregulation of cell cycle, senescence and p53-mediated apoptosis. J Pathol. 2015, Apr 29. [Epub ahead of print]
4. Li CH, Chen Y. Targeting EZH2 for Cancer Therapy: Progress and Perspective. Curr Protein Pept Sci.2015, 16(6):559-70.
5. Shen J, Xiao Z, Wu WK, Wang MH, To KF, Chen Y, Yang W, Li MS, Shin VV, Tong JH, Kang W, Zhang L, Li M, Wang L, Lu L, Chan RL, Wong SH, Yu J, Chan MT, Chan FK, Sung JJ, Cheng AS, Cho CH. Epigenetic silencing of miR-490-3p reactivates the chromatin remodeler SMARCD1 to promote Helicobacter pylori-induced gastriccarcinogenesis. Cancer Res.2015;75:754-65.
6. Xiao Z, Chen Y. Small molecule targeting miR-34a for cancer therapy,Molecular & Cellular Oncology, 2015,2:1, e977160.
7. Wang J, Dong L, Xu L, Chu ES, Chen Y, Shen J, Li X, Wong CC, Sung JJ, Yu J. B cell CLL/lymphoma 6 member B inhibits hepatocellular carcinoma metastases in vitro and in mice. Cancer Lett.2014 Dec 28;355(2):192-200.
8. Xiao Z, Li CH, Chan SL, Xu F, Feng L, Wang Y, Jiang JD, Sung JJY, Cheng CHK,Chen Y. A small molecule modulator of the tumor suppressor miRNA-34a inhibits the growth of hepatocellular carcinoma.Cancer Res.2014;74(21):6236-47.
9. Li CH, Xu F, Chow SC, Feng L, Yin D, Ng TB, Chen Y. Hepatitis B virus X protein promotes hepatocellular carcinoma transformation through interlukin-6 activation of microRNA-21 expression.Eur J Cancer. 2014;50(15):2560-9.
10. Ma JY, Zhou X, Fu J, Hu T, Or PM, Feng R, He CY, Chen WJ, Zhang X, Chen Y*, Wang Y, Yeung JH. Metabolite profiling analysis of FR429, an ellagitannin purified from Polygonum capitatum, in rat and human liver microsomes, cytosol and rat primary hepatocytes in vitro. (*corresponding author).Chem Biol Interact. 2014 Jun 10. pii: S0009-2797(14)00181-1. doi: 10.1016/j.cbi.2014.06.002.
11. He CY, Fu J, Ma JY, Feng R, Tan XS, Huang M, Shou JW, Zhao ZX, Li XY, Zhang XF, Chen Y*, Wang Y. Biotransformation and metabolic profile of extracts with potential anti-tumor activity from a traditional Miao-nationality herbal medicine, Polygonum capitatum in vitro. (*corresponding author).Molecules, 2014 Jul 16;19(7):10291-308.
12. Tang SC,Chen Y. Novel Therapeutic Targets for Pancreatic Cancer.World J Gastroenterol. 2014 Aug 21;20(31):10825-10844.
13. Zhao J, Feng Y, Yan H, Chen Y, Wang J, Chua B, Miao J, Yin D. β-arrestin2/miR-155/GSK3β regulates transition of 5’-azacytizine–induced Sca-1–positive Cells to Cardiomyocytes.J Cell Mol Med. 2014 Aug;18(8):1562-70.
14. Lee KY, Chan KY, Tsang KS, Chen Y, Kung HF, Ng PC, Li CK, Leung KT, Li K. Ubiquitous Expression of MAKORIN-2 in Normal and Malignant Hematopoietic Cells and Its Growth Promoting Activity. PLoS One. 2014;9:e92706.
15. Xiao ZG, Chow SC, Li CH, Tang SC, Tsui SKW, Lin ZX, Chen Y. Role of microRNA-95 in the anticancer activity of Brucein D in hepatocellular carcinoma.Eur J Pharmacol,2014,728:141-150.
16. Zhang Y, Liu J, Tian XY, Wong WT, Chen Y, Wang L, Luo J, Cheang WS, Lau CW, Kwan KM, Wang N, Yao X, Huang Y. Inhibition of Bone Morphogenic Protein 4 Restores Endothelial Function in db/db Diabetic Mice. Arterioscler Thromb Vasc Biol. 2014, 34(1):152-9.
17. Wang Y, Ma JY, Chow SC, Li CH, Xiao ZG, Feng R, Fu J, Chen Y. A potential antitumor ellagitannin, davidiin, inhibited hepatocellular tumor growth by targeting EZH2.Tumor Biology,2014, 35:205-12.
18. Li CH, Chen Y. Targeting long non-coding RNAs in cancer: progress and perspective.Int J Biochem Cell Biol, 2013, 45:1895-1910.
19. Li CH, To KF, Tong JH, Xiao Z, Xia T, Lai PB, Chow SC, Zhu YX, Chan SL, Marquez VE, Chen Y.  Enhancer of Zeste Homolog 2 Silences microRNA-218 in Human Pancreatic Ductal Adenocarcinoma Cells by Inducing Formation of Heterochromatin. Gastroenterology, 2013,144:1086-1097.
20. Fu J, Ma JY, Zhang XF, Wang Y, Feng R, Chen Y*, Tan XS, Zhang YY, Sun YP, Zhou Y, Ma C, He CY, Zhao ZX, Du XW.Identification of metabolites of FR429, a potential antitumor ellagitannin, transformed by rat intestinal bacteria in vitro, based on liquid Chromatography-ion trap-time of flight mass spectrometry analysis.J Pharm Biomed Anal. 2012, 71:162-7.
21. Fok KL, Chung CM, Yi SQ, Jiang X, Sun X, Chen H, Chen Y, Kung H, Tao Q, Diao R, Chan H, Zhang XH, Chung YW, Cai Z, Chan HC. STK31 maintains the undifferentiated state of colon cancer cells. Carcinogenesis. 2012;33:2044-53.
22. Wong CCM, Zhang L, Li ZJ, Wu WKK, Ren SX, Chen Y, Ng TB, Cho CH. Protective Effects of Cathelicidin-Encoding Lactococcus lactis in Murine Ulcerative Colitis.J Gastroenterol Hepatol. 2012, 27:1205-12.
23. Tian XY, Yung LH, Wong WT, Liu J, Leung FP, Liu L, Chen Y, Kong SK, Kwan KM, Ng SM, Lai PB, Yung LM, Yao X, Huang Y. Bone morphogenic protein-4 induces endothelial cell apoptosis through oxidative stress-dependent p38MAPK and JNK pathway. J Mol Cell Cardiol. 2012;52:237-44.
24. Yip WK, Cheng ASL, Zhu R, Lau SK, Chen Y, Sung JG, Lai PB, Ng EK, Yu J, Wong N, To KF, Wong WS, Sung JJY, Chan HLY. Carboxyl-terminal truncated HBx regulates a distinct microRNA transcription program in hepatocellular carcinoma development.PLoS One, 2011;6:e22888.
25. Cheng ASL, Lau SS,Chen Y, Kondo Y, Li MS, Feng H, Ching AK, Cheung PK, Wong KH, Jin H, Choy R, Yu J, To KF, Wong N, Huang TH, Sung JJY. EZH2–mediated concordant repression of Wnt antagonists promotes β- catenin –dependent hepatocarcinogenesisi.Cancer Res, 2011;71: 4028-4039.
26. Cai MY, Tong ZT, Zheng F, Liao YJ, Wang Y, Rao HL, Chen Y, Wu QL, Liu YH, Guan XY, Lin MC, Zeng YX, Kung HF, Xie D. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. Gut, 2011;60:967-76.
27. Yue Y, Jin F, Deng R, Cai J, Chen Y, Lin MC, Kung HF, Wu C. Revisit complexation between DNA and polyethylenimine-Effect of uncomplexed chains free in the solution mixture on gene transfection. J Control Release. 2011; 155:67-76.
28. Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, Chen Y, Peng Y, Yao KT, Kung HF, Li XP. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2.Cancer Res. 2011;71:225-33.
29. Lan FF, Wang H, Chen Y, Chan CY, Ng SS, Li K, Xie D, He ML, Lin MC, Kung HF. Has-let-7g inhibits proliferation of hepatocellular carcinoma cells by down-regulation of c-Mys and up-regulation of p16(INK4A).Int J Cancer, 2011; 128:319-31.
30. Zhang J, He ML, Dong Q, Xie WD, Chen Y, Lin MC, Leung PC, Zhang YO, Kung HF. Aqueous extracts of Fructus Ligustri Lucidi enhance the sensitivity of human colorectal carcinoma DLD-1 cells to doxorubicin-induced apoptosis via TBX3 suppression. Integr Cancer Ther, 2011;10:85-91.
31. Diao S, Zhang JF, Wang H, Chen Y*, Kung HF. Proteomic identification of microRNA-122a target proteins in hepatocellular carcinoma.Proteomics, 2010, 10:3723-31.
32. Wong WT, Tian XY, Chen Y, Leung FP, Wong SL, Lee HK, Ng CF, Yao X, Vanhoutte, Tipoe G, Huang Y. COX-2 up-regulation and prostaglandin F2α mediate bone morphogenic protein 4-induced endothelial dysfunction in hypertension. Circ Res,2010,107:984-991.
33. Li XY, Chen Y, Zhou KY, Zhang MH, Luo HQ, Kung HF, Zhou X. Overexpression of Bax inhibitor-1 (BI-1) induces cell transformation in NIH3T3 cells. Cell Biol Int, 2010, 34:1099-104.
34. Rao ZY, Cai MY, Yang GF, He LR, Mai SJ, Hua WF, Liao YJ, Deng HX, Chen Y, Guan XY, Zeng YX, Kung HF, Xie D. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis. 2010; 31:1576-83.